

## FORM 7

### MONTHLY PROGRESS REPORT

Name of CSE Issuer: **M-Pharmaceutical Inc. (“M-Pharmaceutical”)**

Trading Symbol: MQ

Number of Outstanding Listed Securities: **33,150,355**

**Date: May 9<sup>th</sup>, 2016**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the CSE Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the CSE.ca website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the CSE Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**M Pharmaceutical Inc. (“the Company”) is committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life of people affected by obesity.**



The Company also has exclusive rights to (i) the eMosquito, for automatic and autonomous monitoring of blood glucose by diabetics and (ii) Trimtec, gastrointestinal neurostimulators using a laparoscopically-implantable technique for the treatment of obesity without permanent anatomical modification of the stomach. As previously advised, the Company has minimized ongoing investment in these technologies and is reviewing potential opportunities to divest or partner these technologies. The Company advises that it may not be able to find appropriate divestiture or partnership opportunities for these technologies. In the case of Trimtec, the exclusive rights have been licensed from UTI Limited Partnership (the technology transfer and commercialization organization at the University of Calgary). If an appropriate divestiture or partnership is not consummated for Trimtec in the near future, it is likely that the Company will return the technology rights to UTI Limited Partnership pursuant to the terms of the technology license agreement between UTI Limited Partners and the Company.

2. Provide a general overview and discussion of the activities of management. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

During March 2016 ongoing, M Pharma also announced that the previously announced letter of intent to acquire reformulated orlistat from Chelatexx, LLC has been allowed to lapse by the parties. The Company will be looking at additional opportunities.

On April 4, 2016, Mr. Brian Keane was announced as the New Interim President and CEO.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None applicable.**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**None applicable.**



6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**On March 15, 2016 ongoing, M Pharma also announced that the previously announced letter of intent to acquire reformulated orlistat from Chelatexx, LLC has been allowed to lapse by the parties. The Company will be looking at additional opportunities.**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**None applicable.**

8. Describe the acquisition of new customers or loss of customers.

**Not applicable.**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**Not applicable.**

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**Not applicable.**

11. Report on any labour disputes and resolutions of those disputes if applicable.

**Not applicable.**

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**M Pharmaceutical Inc. did not become a party to any legal proceedings during this period.**

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**No indebtedness occurred during this period.**

14. Provide details of any securities issued and options or warrants granted.

**Not applicable during this period.**



15. Provide details of any loans to or by Related Persons.

**No loans were made to or by Related Persons during this period.**

16. Provide details of any changes in directors, officers or committee members.

**On April 4, 2016, Brian Keane was announced as the New interim President and CEO.**

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

**Not applicable during this period.**

### **Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

**Dated: May 9th, 2016**

Brain D. Keane. CEO

//Brian D. Keane//

Signature

Director

Official Capacity

<b><i>Issuer Details</i></b>	For Month	Date of Report
Name of Issuer	End March,	May 9, 2016
M-Pharmaceutical Inc.	2016	
Issuer Address		
430-580 Hornby Street		



City/Province/Postal Code Vancouver, B.C. V6C 3B6	Issuer Fax No.	Issuer Fax No. (604) 428 0512
Contact Name Brain D. Keane	Contact Position Interim President & CEO	Contact Telephone No. (604) 428 0511
Contact Email Address <a href="mailto:info@m-pharma.ca">info@m-pharma.ca</a>	Web Site Address <a href="http://www.m-pharma.ca">www.m-pharma.ca</a>	